|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
6/1/2009 9:16:41 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today announced new data highlighting the anti-angiogenic and tumor-targeting properties of TM601 in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). In a clinical study of patients with recurrent glioblastoma, the first cohort of patients analyzed showed correlative reductions in vascular perfusion and prolongation of progression-free survival. A separate clinical study, utilizing radiolabeled TM601, demonstrated highly specific tumor uptake of intravenously delivered 131I-TM601 in several different primary and metastatic tumor types, including glioma, metastatic melanoma, pancreatic cancer, prostate cancer and non-small cell lung cancer. Of note, selective tumor-specific uptake of 131I-TM601 was observed in six cases of melanoma with metastases in the brain, demonstrating that 131I-TM601 localized to metastatic tumors across the blood-brain barrier. TM601 is a novel, wholly synthetic peptide, found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease.
|
|
|
|
|
|
|
|
|
|
|